Parexel announces new CEO

Parexel has announced that its CEO, Jamie Macdonald will retire, with the company’s current chief operating and growth officer Peyton Howell taking over as CEO, effective 15 May 2024.
Peyton joined Parexel in 2018 as chief commercial and strategy officer, having launched its biotech business unit in January 2019.
Outgoing CEO, Jamie Macdonald commented: “It’s been a privilege to lead Parexel during this critical period in the company’s strategic transformation. Our commitment and focus on the patient have continued to differentiate Parexel, drive our focus on innovation and ultimately strengthen our ability to develop new therapies that enhance and save patient lives. We have an incredibly talented team and leader in Peyton as our next CEO. On a personal note, I’m proud of my time with Parexel and to have been part of the CRO industry for 30 years. With the company well positioned for growth, now is the right time for me to retire and spend more time with my family. Following the transition, I look forward to continuing to support Parexel as a Board member and remaining an investor. I’m truly grateful for my time with this amazing organisation and to have been part of such an incredible team.”
Peyton Howell added: “I’m honoured to serve as the next CEO of Parexel. With a focus on the patient, a commitment to our customers and the CRO industry’s best colleagues, we have an exciting future ahead. I’m proud of our growth and accomplishments and look forward to working with Jamie on the transition and with the Board and our leadership team to build on this momentum as we execute on our strategic initiatives, continue profitable growth and generate value for our stakeholders.”